"10.1371_journal.pone.0028754","plos one","2011-12-28T00:00:00Z","Davinder P S Dosanjh; Mustafa Bakir; Kerry A Millington; Ahmet Soysal; Yasemin Aslan; Serpil Efee; Jonathan J Deeks; Ajit Lalvani","Tuberculosis Research Unit, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom; Department of Paediatrics, Marmara University School of Medicine, Istanbul, Turkey; Unit of Public Health, Epidemiology and Biostatistics, School of Population Health and Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom","Conceived and designed the experiments: AL MB. Performed the experiments: DD KM AS MB YA SE. Analyzed the data: DD JD AL MB KM. Contributed reagents/materials/analysis tools: AL JD. Wrote the paper: AL DD. Critical appraisal: MB KM JD AS. Study Coordination: AL MB AS. Enrollment and clinical assessment of study participants: MB AS YA.","The authors have read the journals policy and have the following conflicts: The ESAT-6/CFP-10 ELISpot was commercialized by an Oxford University spin-out company (Oxford Immunotec Ltd, Abingdon, UK) in which Oxford University and Professor Lalvani have a minority share of equity and entitlement to royalties. AL, KM and DD are inventors of patents in the field of T-cell-based diagnosis. These are listed as follows: Title: Clinical Correlates, Number: 0605474.6; Title: Biomarker, Number: 0618127.5; Title: Mycobacterium tuberculosis infection diagnostic test, Number: 0406271.7; Title: Diagnostic Test, Number: 0906215.9. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","12","Davinder P S Dosanjh","DPSD",8,TRUE,2,6,5,2,TRUE,TRUE,FALSE,0,NA,FALSE
